Hot flash

MENOPAUSE HOT FLASHES EXTINGUISHED

Retrieved on: 
Tuesday, February 27, 2024
Woman, Hormone, Hot flash, IRB, Health, Journal, Nutraceutical, North American Menopause Society

DENVER, Feb. 27, 2024 /PRNewswire/ -- Today, health and wellness company, Rebalance Health announced results and outcomes from a 104 subject IRB-approved open label study focused on the company's new Hot Flash System™.  The study revealed that women saw an average of 80% reduction in hot flashes and other menopausal symptoms, with no side effects. The initial findings were first published by the North American Menopause Society and have since been finalized and published by a second peer reviewed journal, The Journal of Nutraceuticals and Food Science.

Key Points: 
  • New Study from Rebalance Health Shows 80% Decrease in Hot Flashes, Measurable Reduction in Other Menopause Symptoms
    DENVER, Feb. 27, 2024 /PRNewswire/ -- Today, health and wellness company, Rebalance Health announced results and outcomes from a 104 subject IRB-approved open label study focused on the company's new Hot Flash System™.
  • The study revealed that women saw an average of 80% reduction in hot flashes and other menopausal symptoms, with no side effects.
  • The initial findings were first published by the North American Menopause Society and have since been finalized and published by a second peer reviewed journal, The Journal of Nutraceuticals and Food Science .
  • Rebalance Health's products support cortisol levels through a proprietary delivery system that allows the body to rebalance hormones naturally.

EMBR LABS APPOINTS CHIEF MEDICAL OFFICER FOLLOWING MAJOR INTELLECTUAL PROPERTY WINS

Retrieved on: 
Thursday, November 16, 2023
Sleep, Woman, Hot, Research, IP, Hot flash, Menopause, HSA, Patient, Nation, Prostate cancer, System, FSA, Cancer, Obstetrics and gynaecology, Temperature, OTC, Nursing, Embres-et-Castelmaure

BOSTON, Nov. 16, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading wearable that utilizes temperature for wellness applications, today announced the formal appointment of Dr. Maria Sophocles as Embr Labs' Chief Medical Officer.

Key Points: 
  • BOSTON, Nov. 16, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading wearable that utilizes temperature for wellness applications, today announced the formal appointment of Dr. Maria Sophocles as Embr Labs' Chief Medical Officer.
  • "I am thrilled to join the Embr Labs team and support their mission to improve lives through the use of temperature regulation.
  • Embr Labs was granted five additional utility patents in the US and Japan (US11701250B2, US11759350B2, US11755083B2, JP7333575B2, JP7319691B2).
  • These patents strengthen Embr Labs' competitive advantage and are valuable additions to the existing IP assets that enabled Embr Lab's $35 million intellectual property-based financing this year.

Embr Labs and UMass Amherst Develop Technology that Can Predict Hot Flashes

Retrieved on: 
Wednesday, September 13, 2023
Partnership, University, North American Menopause Society, Wrist, Psychology, Embres-et-Castelmaure, Perception, National Science Foundation, Sleep, Woman, University of Bath Department of Psychology, Temperature, Brain, Biomarker, IALS, Hot, Hot flash, Science, Cloud computing, Iran National Science Foundation, Patent, Manuscript, Machine learning, Algorithm, Menopause, System, Pharmaceutical industry, Video game, Computer data storage, Forging, University of Massachusetts Amherst

BOSTON, Sept. 13, 2023 /PRNewswire/ -- Boston-based technology startup Embr Labs is announcing the next stage of development for the Embr Wave: a consumer wearable that utilizes temperature sensations as haptic therapy. Together with researchers at the University of Massachusetts Amherst's Institute for Applied Life Sciences (IALS), the company has co-developed the ability to predict a menopausal hot flash before it occurs and then activate immediate cooling on the Embr Wave to mitigate or fully alleviate a hot flash.

Key Points: 
  • Boston-based technology startup Embr Labs is announcing the next stage of development for the Embr Wave.
  • The team generated the largest data set of digital biomarkers for hot flashes ever collected and utilized machine learning to develop algorithms that can predict a hot flash before it is even felt by a person.
  • "Hot flashes occur in 75% of women and can persist for up to a decade," says Matt Smith, co-founder and CTO of Embr Labs.
  • By delivering automatic cooling for hot flash relief, we are realizing the holy grail for natural hot flash management."

FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause

Retrieved on: 
Friday, May 12, 2023
Vaginal bleeding, Infection, Kidney disease, Priority review, Liver, Food, Pediatrics, Diarrhea, Center for Drug Evaluation and Research, Chills, Menopause, Liver disease, Stroke, Skin, Quality of life, Woman, Liver injury, History, Abdominal pain, Hot, Hot flash, Hormone, CYP1A2, Vomiting, Thermoregulation, Insomnia, Back pain, Rare, Patient, Perspiration, Nausea, Progesterone, Research, Reproductive medicine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cirrhosis, Flushing, Safety, Pharmaceutical industry, Birth control

SILVER SPRING, Md., May 12, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant) , an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.

Key Points: 
  • SILVER SPRING, Md., May 12, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant) , an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.
  • Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause.
  • "The introduction of a new molecule to treat moderate to severe menopausal hot flashes will provide an additional safe and effective treatment option for women."
  • The effectiveness of Veozah to treat moderate to severe hot flashes was demonstrated in each of the first 12-week, randomized, placebo-controlled, double-blind portions of two phase 3 clinical trials.

Rebalance Health Launches Groundbreaking Products with Proven Clinical Efficacy in Relieving Hot Flashes, Anxiety, and Boosting Testosterone

Retrieved on: 
Tuesday, May 9, 2023
Hot flash, Hormone replacement therapy, Overalls, Woman, Multimedia, Hot, Hormone, Regenerative medicine, HRT, CO, Rebalance, Testosterone, Health, Mental health, Pig, Pharmaceutical industry

The improved sleep quality provided by the Rebalance Systems™ enables the hormone system to rebalance naturally, resulting in greater overall health.

Key Points: 
  • The improved sleep quality provided by the Rebalance Systems™ enables the hormone system to rebalance naturally, resulting in greater overall health.
  • As Rebalance Health Founder and CEO Justin Hai explains, "Every good day starts with a restorative night's sleep."
  • Our recent studies have revealed that by taking the Rebalance System™, men boosted their testosterone by 100 points over an 8-week period.
  • The Testosterone System is priced at $80, while The Anxiety System and The Hot Flash System are priced at $75 each.

The National Menopause Foundation Adds Experts in Women's Health, Advocacy, and Social Justice to Its Board of Directors

Retrieved on: 
Wednesday, March 29, 2023
Medicine, Black Girl, Public affairs, Pharmaceutical Research and Manufacturers of America, Political science, Social justice, United Nations Foundation, Menopause, Happiness, MM, Fairfield University, Executive, University, Ageing, PRWeek, Hot Flash Havoc, The New York Times, Knowledge, Broadcast journalism, Hot flash, Communication studies, Communication, MGM Resorts International, Black Girl Hockey Club, Pharmacy, The Washington Post, University of North Carolina at Chapel Hill, Public policy, Democratic National Committee, The Works (film), Democratic National Committee cyber attacks, Point-blank range, Berkeley, DC, Woman, Female, Subject matter, Industrial Affairs Committee (Iceland), Health, Nursing, Management, Northwestern University

ALEXANDRIA, Va., March 29, 2023 /PRNewswire/ -- The National Menopause Foundation is pleased to announce the addition of three new members to its Board of Directors.

Key Points: 
  • ALEXANDRIA, Va., March 29, 2023 /PRNewswire/ -- The National Menopause Foundation is pleased to announce the addition of three new members to its Board of Directors.
  • "By expanding our Board of Directors with female executive leaders from a variety of industries, we broaden the scope of expertise to help lead the National Menopause Foundation and to fulfill its mission.
  • We will continue to strengthen our capacity and reach and grow the organization into the most trusted resource for women on their menopause journey," said Claire Gill, Founder, National Menopause Foundation.
  • The National Menopause Foundation website – www.nationalmenopausefoundation.org – features information to educate, inspire and empower women as they approach and experience menopause.

Embr Wave Now Available in the United Kingdom

Retrieved on: 
Thursday, September 29, 2022
Adoption, Workforce, Temperature, Woman, Brain, Intel Capital, Autonomic nervous system, Ageing, No. 7, MIT, Hot flash, Wave, Perspiration, Forbes, Partnership, Labs, Invention, Menopause, Insomnia, Design, Quality of life, Embres-et-Castelmaure, Time (magazine), Sleep, Flash, Boot, Tata Research Development and Design Centre, Nightclub, Video game

BOSTON, Sept. 29, 2022 /PRNewswire/ -- Embr Labs announced today that they have entered into a strategic partnership to launch an innovative women's health product to provide immediate relief from hot flashes during menopause. Embr Wave 2, a sleek wearable that cools or warms at the touch of a button, will now be made available to women in the UK.

Key Points: 
  • Embr Wave 2, a sleek wearable that cools or warms at the touch of a button, will now be made available to women in the UK.
  • The Embr Wave provides immediate relief for women who experience hot flashes during menopause through the application of natural temperature sensations that balance the body's nervous system.
  • These sensations can be personalized for more effective relief using the Embr Wave 2 mobile app.
  • Embr Labs has won numerous awards for the Embr Wave, including the AARP Innovation in Aging Award, Time Magazine's Best Inventions, and the iF Design

Women in the Workforce Face Significant Challenges Due to Menopause, Rank Their 50s as Most Challenging Decade at Work, Yet Receive Minimal Support, New Survey Reveals

Retrieved on: 
Thursday, September 22, 2022
MPH, Adoption, Workforce, Freezing, Woman, Hot flash, Fertility preservation, Topical steroid withdrawal, Metabolism, Workplace, IVF, Mental health, Program, Fertility, Menopause, Taboo, Pregnancy, CEO, Perception, Family, Anxiety, Testosterone, Awareness, Job satisfaction, Fatigue, Weight gain, Multimedia, Birth control, Health insurance, Public relations, Medicine, MD, Carrot

MENLO PARK, Calif., Sept. 22, 2022 /PRNewswire/ -- Women in the workforce face significant challenges due to menopause, but they receive minimal support from employers, according to a new Menopause in the Workplace survey from Carrot Fertility. As the leading global fertility healthcare and family-forming benefits provider for employers and health plans, the company commissioned the survey ahead of Menopause Awareness Month to understand the effects of menopause on careers, identify resources available to menopausal women, and bring more awareness to menopause to further destigmatize it in the workplace. An estimated 1.1 billion women worldwide will have experienced menopause by 2025, with millions more going through perimenopause.

Key Points: 
  • An estimated 1.1 billion women worldwide will have experienced menopause by 2025, with millions more going through perimenopause.
  • Most women reported the need to take time off or faced other serious challenges in the workplace during menopause and perimenopause.
  • A majority (54%) have encountered at least one menopause-driven work challenge, including loss of work time and job security concerns.
  • Of those who took time off, 59% felt they needed to conceal the reason for the time away.

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

Retrieved on: 
Tuesday, June 21, 2022
NCCN, Doctor of Philosophy, Motivation, Flash, Hematology, Breast cancer, Bioethics, Hot flash, Review, Education, Department, Nominal interest rate, FACP, Mortality, Epidemiology, National Comprehensive Cancer Network, Harborside, Journal of the National Comprehensive Cancer Network, Oncology, School, Decision-making, ER, Cancer, Research, DSF, AHT, Precision medicine, Report, Clinical trial, MD, Master of Science, Epistasis, Policy, Health, Aromatase, Caregiver, Strathcona County, Twitter, Public health, Patient, Medicine, Prognosis, Zhejiang University, Public policy, Medical imaging, Birth control, Pharmaceutical industry, Health insurance, Biostatistics

PLYMOUTH MEETING, Pa., June 21, 2022 /PRNewswire/ -- New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical trial findings that show adjuvant hormone therapy (AHT)-related hot flashes predict better outcomes for estrogen receptor-positive (ER+) breast cancer. The population-based study looked at 7,152 chemotherapy-free patients with breast cancer in Sweden between 2006 and 2019 and found patients who were treated for hot flashes after beginning AHT were actually more likely to have worse outcomes. Patients who were subsequently treated for hot flashes had a 14.2% higher early discontinuation rate, which may account for the significantly shorter length of disease-free survival (DSF).

Key Points: 
  • "Cancer care providers need to be aware that prescribing symptom-relieving drugs to patients with treatment-related side effects may not be enough to prevent treatment discontinuation."
  • Hot flashes were one of the most common side effects, but only led to an 8%-28% rate of treatment discontinuation.
  • "Precision medicine based on the patient's genetic background may help to reduce treatment discontinuation," said senior author Kamila Czene, PhD, Karolinska Institutet.
  • Complimentary access to " Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis " is available until September 10, 2022.

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

Retrieved on: 
Tuesday, June 21, 2022
NCCN, Doctor of Philosophy, Motivation, Flash, Hematology, Breast cancer, Bioethics, Hot flash, Review, Education, Department, Nominal interest rate, FACP, Mortality, Epidemiology, National Comprehensive Cancer Network, Harborside, Journal of the National Comprehensive Cancer Network, Oncology, School, Decision-making, ER, Cancer, Research, DSF, AHT, Precision medicine, Report, Clinical trial, MD, Master of Science, Epistasis, Policy, Health, Aromatase, Caregiver, Strathcona County, Twitter, Public health, Patient, Medicine, Prognosis, Zhejiang University, Public policy, Medical imaging, Birth control, Pharmaceutical industry, Health insurance, Biostatistics

PLYMOUTH MEETING, Pa., June 21, 2022 /PRNewswire/ -- New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical trial findings that show adjuvant hormone therapy (AHT)-related hot flashes predict better outcomes for estrogen receptor-positive (ER+) breast cancer. The population-based study looked at 7,152 chemotherapy-free patients with breast cancer in Sweden between 2006 and 2019 and found patients who were treated for hot flashes after beginning AHT were actually more likely to have worse outcomes. Patients who were subsequently treated for hot flashes had a 14.2% higher early discontinuation rate, which may account for the significantly shorter length of disease-free survival (DSF).

Key Points: 
  • "Cancer care providers need to be aware that prescribing symptom-relieving drugs to patients with treatment-related side effects may not be enough to prevent treatment discontinuation."
  • Hot flashes were one of the most common side effects, but only led to an 8%-28% rate of treatment discontinuation.
  • "Precision medicine based on the patient's genetic background may help to reduce treatment discontinuation," said senior author Kamila Czene, PhD, Karolinska Institutet.
  • Complimentary access to " Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis " is available until September 10, 2022.